Finally, the results contribute to other findings suggesting that modification of APP processing, and associated downstream glutamatergic signaling cascades, may be beneficial in populations with altered APP metabolism, including aged individuals (Rodrigue et al., 2012) and those at high risk of AD. This evidence concerns the gene APP and Alzheimer disease.